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Abbreviations 
AhR: Aryl hydrocarbon receptor 
BC: Breast cancer tissue 
BCRP: Breast cancer resistance protein 
BSA: Bovine serum albumin 
BSP: Bromosulfophthalein 
CAR: Constitutive androstane receptor 
CCNDI: Cyclin D1 
CI: Confidence interval 
DMEM: Dulbecco's modified Eagle's medium 
EC50: Half maximal (50%) effective concentration 
EDTA: Ethylenediaminetetraacetic acid 
ELISA: Enzyme-linked immunosorbent assay 
ER: Estrogen receptor 
ERE: Estrogen responsive element 
E1: Estrone 
E1S: Estrone-3-sulfate 
E2: 17β-Estradiol 
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FBS: Fetal bovine serum 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase 
HER2: Human epidermal growth factor receptor 2 
HEPES: 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
LI: Labeling index 
Na
+
/K
+
-ATPase: Sodium potassium ATPase  
NB: Normal breast tissue 
Nrf2: Nuclear factor erythroid 2-related factor 2 
OATP: Organic anion-transporting polypeptide 
PBS: Phosphate-buffered saline 
PCR: Polymerase chain reaction 
PgR: Progesterone receptor 
PKC: Protein kinase C 
PPARα: Peroxisome proliferator-activated receptor α 
PXR: Pregnane X receptor 
RT: Reverse transcription 
SD: Standard deviation 
SDS: Sodium dodecyl sulfate 
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SE: Standard error 
SLCO: Solute carrier organic anion 
STS: Steroid sulfatase 
T-PBS: PBS containing 0.5% Tween-20 
Tris: Tris (hydroxymethyl) aminomethane 
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Introduction 
 Breast cancer is the most common cancer in women. About two thirds of invasive 
breast cancers express an estrogen receptor (ER), and estrogens play an important role in the 
proliferation of ER-positive breast cancer cells [1, 2]. Two major pathways, aromatase and 
sulfatase pathways, are involved in the production of biologically active estrogens (mainly 
17β-estradiol, E2) in breast cancer cells [3, 4], and sulfatase activity has been reported to be 
higher than aromatase activity [5, 6]. Recent studies have revealed that steroid sulfatase (STS), 
which converts steroid sulfates into the unconjugated forms in the sulfatase pathway, may have 
a key role in the growth of cancer cells [7]. Thus, inhibition of STS activity has been proposed 
as a strategy to treat ER-positive breast cancer [8-11]. In the sulfatase pathway, estrone-3-sulfate 
(E1S) is a substrate of STS and precursor/reservoir of estrogens. The half-life of E1S is much 
longer than that of its unconjugated form, and the concentration of E1S in malignant breast 
tissues is greater than that in non-malignant tissues [6, 12]. Taken together, E1S may play an 
important role in the proliferation of ER-positive breast cancer cells. Since E1S is a highly 
hydrophilic compound, it likely requires a solute carrier to cross plasma membranes (Figure 1) 
[13-15]. Current evidence suggests several classes of transporter specialized for entry of E1S 
into ER-positive breast cancer cells. 
 Human organic anion-transporting polypeptides (OATPs), which are encoded by 
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SLCO (former SLC21) genes, belong to the family of solute carrier transporters [16, 17]. OATPs 
have been characterized in detail and shown to be transporters responsible for the uptake of 
organic anions. So far, 11 human OATP family members have been identified, and several 
members of the OATP family have been shown to be capable of transporting steroid sulfates, 
including E1S [18, 19]. OATP2B1 recognizes various types of organic anions as substrates and 
has unique substrate specificity with high affinity to E1S [20-22]. OATP2B1 is highly expressed 
in the liver, small intestine, placenta, and platelets and has been reported to be ubiquitously 
distributed in many tissues [16, 18, 19, 23]. Importantly, the abundant expression of OATP2B1 
has been detected in the human mammary gland, and it has been reported that OATP2B1 might 
be the most important transporter accounting for delivery of E1S in both normal breast and 
malignant tissues [24]. However, information on the association between expression level of 
OATP2B1 and proliferation of breast cancer cells is limited. 
 ER-positive breast cancers are classified into at least two subtypes, luminal A-like and 
luminal B-like cancers, by gene expression profiling [25, 26]. Luminal B-like cancers are 
known to have a higher rate of proliferation and to show worse outcomes than those of luminal 
A-like cancers [27-29]. Although luminal B-like cancers are defined as a subtype of ER-positive 
breast cancers, they show high expression levels of proliferation markers including Ki-67 and 
low expression levels or lack expression of estrogen-regulated genes including progesterone 
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receptor (PgR) compared with those in luminal A-like cancers (Table 1) [25, 30-32]. Moreover, 
luminal B-like cancers are thought to rely on another pathway of growth in addition to the 
estrogen pathway [33, 34]. Therefore, endocrine therapy is insufficient and additional agents, 
such as chemotherapeutic agents, are needed in luminal B-like cancers [26]. Conversely, 
luminal A-like cancers are less responsive to chemotherapy and respond well to endocrine 
therapy [26]. Thus endocrine therapy alone should be applied to luminal A-like subtype from 
the viewpoint that chemotherapy causes more serious adverse events. Consequently, it is of 
great importance to clarify luminal subtypes to predict a benefit of an endocrine treatment and 
to identify patients who will receive potential benefit from a particular chemotherapy agent in a 
clinical setting. Many efforts have been made to establish biomarkers that can distinguish 
luminal B-like cancers from all ER-positive cases. However, a classification of luminal subtypes 
is still ambiguous and the absolute biomarkers for the classification have not yet been 
established.  
 The aim of the present study was to investigate the relationship between the 
expression level of OATP2B1 and proliferation of ER-positive breast cancer cells. We 
overexpressed OATP2B1 in MCF-7 cell line, which is widely utilized as a model of ER-positive 
breast cancer cells, to clarify potential role of the transporter on the cell proliferation. The 
expression level of SLCO2B1 mRNA was also assessed in 16 normal and 49 malignant breast 
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tissue samples. Finally, the relationship between uptake of E1S and alteration of the expression 
levels of ERα and Ki-67 was investigated in MCF-7 cells to seek differences between luminal 
A-like and luminal B-like cancers from the viewpoint of uptake transporter for E1S. This is the 
first study to overexpress OATP2B1 in a breast cancer cell line and to directly elucidate the 
effects of overexpression of the transporter for an estrogen precursor on proliferation of 
ER-positive breast cancer cells. 
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Figure 1.  A scheme of E1S uptake for cell proliferation in ER-positive breast cancer. E1, 
estrone 
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Table 1.  Pathological features of luminal subtypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Status Luminal A-like Luminal B-like
ER High High - Low
Tumor size Small Large
PgR High Low - Lack
Ki-67 Low High
Histological
grade
Low High
Response to hormone
therapy
Good Poor
Prognosis Good Poor
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Methods 
Cell culture 
The human breast cancer cell line MCF-7 was obtained from RIKEN Bioresouce 
Center (Tsukuba, Japan). MCF-7 cells were routinely cultured in Dulbecco’s modified Eagle’s 
(DMEM) medium supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 
non-essential amino acids and 10% (v/v) fetal bovine serum (FBS) (Wako, Tokyo, Japan). All 
cells were cultured in a humidified 5% (v/v) CO2 atmosphere at 37℃. In the experiments using 
E2 and E1S, phenol red-free DMEM (Wako) containing charcoal dextran-treated FBS 
(Funakoshi, Tokyo, Japan) (estrogens-free medium) was used to avoid effects of endogenous 
estrogens and phenol red, the latter of which is known to be capable of stimulation to ER. To 
establish MCF-7 cells overexpressing OATP2B1, MCF-7 cells were transfected with OATP2B1 
cDNA subcloned into pcDNA3 (Life Technologies Japan, Tokyo, Japan) by using TransFast 
Transfection Reagent (Promega, Madison, WI) according to the manufacturer’s instructions. 
The cells had been cultured in a medium containing 1.0 μg/μL G418 (Wako) for two weeks, and 
then the overexpression of OATP2B1 was confirmed by Western immunoblot analysis. The 
human embryonic kidney cell line HEK293 overexpressing OATP2B1, which was kindly 
provided by Dr. Tamai [35], was used as a positive control to confirm the overexpression of 
OATP2B1 in MCF-7 cells. In this paper, MCF-7 cells transfected with a control vector and 
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those overexpressing OATP2B1 are designated as MCF-pcDNA3 and MCF-OATP2B1, 
respectively. Similarly, HEK293 cells transfected with a control vector and those overexpressing 
OATP2B1 are designated as HEK-pcDNA3 and HEK-OATP2B1, respectively. 
 
Tissue samples  
Malignant breast tumor tissues were donated from 49 female patients with primary 
invasive breast carcinoma at Chiba University Hospital from 2011 to 2012. Non-malignant 
breast tissues distant from the carcinoma region were obtained from 16 female patients who 
underwent total mastectomy. These tissue samples were immediately soaked in RNAlater RNA 
Stabilization Solution (Life Technologies Japan) and stored at -20℃ until use. None of patients 
who participated in this study received irradiation or chemotherapy before undergoing the 
surgical operation. Data on clinicopathological variables were collected according to the same 
methods in the paper written by Dr. Sakakibara [36]. This study was approved by the Research 
Ethics Committee of the Graduate School of Medicine, Chiba University (Approval No.100) 
and all patients provided written informed consent.  
 
RNA preparation and cDNA synthesis 
Total RNA was extracted from breast tissues and cell lines by using TRIzol (Invitrogen, 
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Carlsbad, CA), and the quality of the isolated RNA was checked by ribosomal RNA ratio and 
absence of degraded bands with a Formaldehyde-Free RNA Gel Kit (Amersco, Cochran Solon, 
OH). Reverse transcription (RT) reaction was carried out with ReverTra Ace qPCR RT Master 
Mix with gDNA Remover (TOYOBO, Osaka, Japan) according to the manufacturer’s 
instructions.  
 
Real-time RT-PCR 
The amount of gene expression was assessed using THUNDERBIRD SYBR qPCR 
Mix (TOYOBO) with an ABI Prism 7000 sequence detection system (Life Technologies Japan). 
The quantitative RT-PCR was performed in a reaction mixture of 20 μL containing SYBR qPCR 
Mix, 0.3 μM of each primer and 100 ng of cDNA. The specific primers used for amplification 
are listed in Table 2. PCR conditions consisted of initial denaturation at 95℃ for 30 sec, 
followed by denaturation at 95℃ for 5 sec, annealing at 58℃ for 20 sec and extension at 72℃ 
for 30 sec. The results were expressed as a relative value after normalization to the RPL13A 
gene expression. 
 
Detection of each SLCO mRNA 
Detection of each SLCO mRNA expression was confirmed in a reaction mixture of  
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25 μL containing 2.5 mM MgCl2, 0.2 mM dNTPs, 2.5 U Ex Taq HS (TaKaRa, Shiga, Japan), 
0.2 μM of each primer and 1.0 μL of cDNA. PCR conditions consisted of initial denaturation at 
94℃ for 3 min, followed by denaturation at 94℃ for 20 sec, annealing at 58℃ for 15 sec and 
extension at 72℃ for 15 sec. The specific primers used for amplification are also listed in 
Table 2. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize the 
expression of the transporter mRNAs. 
 
Protein preparation and deglycosylation 
Total protein was extracted from MCF-7 cells. The cells were collected and suspended 
in an extraction buffer consisting of 10 mM EDTA, 150 mM sodium chloride, 30 mM Tris-HCl 
(pH = 7.4), 0.5% (w/v) Triton X-100 and 0.5% (w/v) sodium cholate. After freezing and 
thawing twice, suspended cells were centrifuged at 13,000 rpm. For extraction of plasma 
membrane fractions from MCF-7 cells and HEK293 cells, the ProteoExtract Transmembrane 
Protein Extraction Kit (Novagen, Darmstadt, Germany) was used according to the 
manufacturer’s instructions. Enzymatic deglycosylation of plasma membrane fractions was 
performed with Protein Deglycosylation Mix (New England Biolabs, Ipswich, MA) according 
to the manufacturer’s recommendations. The deglycosylation was carried out to confirm 
whether OATP2B1 overexpressed in MCF-7 cells was identical with that overexpressed in 
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HEK293 cells. 
 
Immunoblot analysis 
Western immunoblot analysis was carried out using polyvinylidene difluoride 
membrane after 9.0% (w/v) sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.  
After blocking with 3% (w/v) bovine serum albumin (BSA) in Tris-buffered saline for 1 h at 
room temperature, the membrane were incubated overnight at 4℃ with a primary antibody. The 
membrane was then incubated with a secondary antibody for 1 h at room temperature. Protein 
bands were visualized by using ECL Western Blotting Detection Reagent (GE Healthcare, 
Tokyo, Japan) and LAS-1000 plus (Fujifilm, Tokyo, Japan). Protein concentrations were 
determined using a BCA Protein Assay Reagent Kit (Pierce, Rockford, IL) according to the 
manufacture’s protocol. Polyclonal rabbit anti-OATP2B1 antibody kindly provided by Dr. 
Tamai [37], monoclonal mouse anti-alpha 1 Sodium Potassium ATPase antibody 
(Na
+
/K
+
-ATPase) (Abcam, Cambridge, MA), polyclonal rabbit anti-ERα antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA), polyclonal rabbit anti-Ki-67 antibody (Abcam) and polyclonal 
rabbit anti-β-actin (Santa Cruz Biotechnology) were used as primary antibodies. Horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Wako) and goat anti-mouse IgG (Santa Cruz 
Biotechnology) were used as secondary antibodies. Can Get Signal (TOYOBO) was used to 
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dilute all of the antibodies.  
 
Immunocytochemistry 
Cells were plated on a cover glass. On the day after plating, cells were fixed with 3.7% 
(w/v) formaldehyde in phosphate-buffered saline (PBS) for 10 min. After washing three times 
with ice-cold PBS, the cells were permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10 
min and incubated with 3% (v/v) H2O2 for 10 min to block endogenous peroxidase activity. 
After washing twice with ice-cold PBS containing 0.5% (v/v) Tween-20 (T-PBS), nonspecific 
binding of antibodies to the target protein was blocked with 3% (w/v) BSA. Polyclonal rabbit 
anti-OATP2B1 antibody was applied overnight at 4℃. The next day, the cells were washed 
three times with ice-cold T-PBS and a biotinylated anti-goat IgG was applied for 30 min at room 
temperature. Can Get Signal immunostain (TOYOBO) was used to dilute both antibodies. After 
washing three times with ice-cold T-PBS, the cells were incubated by using a VECTASTAIN 
Elite ABC Kit (Vector Laboratories, Burlingame, CA) according to the manufacturer’s 
instructions. The immune complex was visualized by precipitation of diaminobenzidine in the 
presence of H2O2. The cells were washed again, counterstained with haematoxylin, dehydrated, 
cleared, and mounted.  
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Cell proliferation assay 
MCF-7 cells were plated at 3,000 cells/well in 24-well plates and cultured in 
estrogens-free medium for 2 days. After incubation with the medium containing test compounds 
for 5 days, the cells were treated with trypsin, and cell numbers were counted using trypan blue 
solution.  
 
Luciferase assay  
MCF-7 cells were plated at 5.0×10
5
 cells/well in 24-well plates in estrogens-free 
medium for 2 days. On the day after precultureing, the cells were transiently co-transfected with 
reporter constructs of pGL3-ERE (0.25 μg/well), in which five copies of estrogen responsive 
element (ERE) was inserted upstream of the luciferase coding region, and renilla reniformis 
pGL4.74 Vector (5.0 ng/well) (Promega) using TransFast Transfection Reagent (Promega) 
according to the manufacturer’s recommendations. pGL3-ERE was kindly provided by 
Sumitomo Chemical. The firefly and renilla luciferase activities were determined using the 
Dual-Luciferase Reporter Assay System (Promega) and Gene-Light (MICROTEC, Chiba, 
Japan). 
 
ELISA for E2 secretion 
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MCF-7 cells were plated at 1.0×10
4
 cells/well in 96-well plates and cultured in 
estrogens-free medium for 2 days. After incubation with the medium containing E1S for 72 h, 
the media were collected and the E2 concentrations were determined using the enzyme 
immunoassay DRG Estradiol ELISA Kit (DRG, Springfield, NJ) according to the 
manufacturer’s instructions. 
 
Transport assay  
MCF-7 cells were cultured in estrogens-free medium for 2 days. On the day after 
pre-incubation, the medium was changed to a transporting buffer (TB) consisting of Hanks' 
balanced salt solution supplemented with 25 mM HEPES (pH = 7.4). After incubation with TB 
for 20 min, transporting reaction was initiated by incubation with TB containing [
3
H]E1S 
(PerkinElmer, Waltham, MA). After the desired period of time, the radioactive medium was 
removed and cells were washed twice with ice-cold PBS and solubilized in 1% Triton X-100 at 
37℃ for 1 h. Then 300 μL of the content of each well was collected and mixed with 3 mL of 
scintillation fluid, and total radioactivity was measured with a scintillation counter. Uptake of 
the radiolabeled probes was normalized to total cellular protein content per well. 
 
Data and statistical analysis 
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Comparison of the difference in mean values between two groups was carried out by 
Student's t-test or Mann-Whitney U test in SPSS software (IBM, Chicago, IL). Pearson’s 
correlation coefficient was applied to assess a relationship between two groups. Kinetic 
parameters obtained from the transport assay were determined by using nonlinear regression 
analysis with Prism ver. 5.01 (MDF, Tokyo, Japan), and curves were fitted to the 
Michaelis-Menten equation V = Vmax･[S]/(Km + [S]). The band intensities were quantified using 
ImagJ 1.46 (http://rsb.info.nih.gov/ij/). P < 0.05 was considered to be statistically significant. 
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Table 2.  Sequences of primers and sizes of amplified products 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148
113
110
107
101
300
125
124
223
167
gatttgaggcacacaaactcctctc
atattccaagggccactgctggaa
gaagagaagaagagtaaggcacc
catatcctcagggctggtgt
gagtttcacccattccacgtaca
ctggtgctcagtgtagccca
ttgaggacctctgtgtatttgtcaa
gcttgccatgcatcaaaata
gggatggtctccttcatcttag
ccattacttccgccatgaat
agctactgtttgctcctaacttgctc
cggcatggtgacgtacaaaccaaa
gcggtcttcattgacacaag
tgattggctatggggctatc
aagaccaacgcaggatccat
catcactgccacccagaaga
cctggaggagaagaggaaagaga
gtggacgtgttgacccttct
tcggtgtcctacttcaaatgtgt
agtctacggggatgctgttg
NM_002046
NM_012423
NM_031226
NM_053056
NM_021094
NM_000351
NM_001122742
NM_017435
NM_013272
NM_007256
ERα
SLCO1C1
SLCO3A1
SLCO2B1
SLCO1A2
GAPDH
RPL13A
Aromatase
CCNDI
STS
Reverse primer (5'-3')Gene name Forward primer (5'-3') Size (bp)Accession Number
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Results  
Overexpression of OATP2B1 in ER-positive breast cancer cells 
 In order to determine the effects of difference in expression level of OATP2B1 on 
proliferation of breast cancer cells, an ER-positive breast cancer-derived MCF-7 cell line stably 
overexpressing human OATP2B1 was established. The expression of OATP2B1 in membrane 
fractions was confirmed by Western immunoblot analysis. Compared with that in 
MCF-pcDNA3, overexpression of the protein with an apparent molecular size of about 116 kDa 
was observed in MCF-OATP2B1, while the size of OATP2B1 expressed in HEK293 cells used 
as a positive control was approximately 84 kDa (Figure 2). Since OATP2B1 was predicted to 
possess two sites for glycosylation in the amino acid sequence [38], membrane proteins 
extracted from each cell line were deglycosylated to determine whether the reason for the 
difference in apparent molecular sizes of OATP2B1 in MCF-7 and HEK293 cells was 
glycosylation. The molecular sizes of both OATP2B1 overexpressed in MCF-7 cells and that 
overexpressed in HEK293 cells shifted to approximately 59 kDa (Figure 3). In addition, 
immunocytochemistry showed specific overexpression of OATP2B1 in both the constructed 
HEK293 cells and MCF-7 cells (Figure 4). These results indicate that OATP2B1 was 
successfully overexpressed in MCF-7 cells. The proliferation of the constructed cells was the 
same with that of the control cells in culture medium contained estrogens, and proliferation of 
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these cell lines was not observed in the medium without estrogens (Figure 5). 
 
Effects of overexpression of OATP2B1 on cell proliferation, stimulation of ER and secretion 
of E2 in ER-positive breast cancer cells 
 It has been reported that the addition of not only E2 but also E1S to the culture 
medium stimulated cell proliferation of hormone-dependent MCF-7 cells [39]. In accordance 
with that report, proliferation of MCF-7 cells was stimulated by both E2 and E1S (Figure 6). 
Growth rate of MCF-OATP2B1 was significantly higher than that of MCF-pcDNA3 when 
treated with E1S (Figure 6B), while a difference in stimulatory effects in these cell lines was 
not observed with E2 treatment (Figure 6A). The apparent logEC50 values for E1S were -8.885 
(95% confidence interval [CI]: -9.049 to -8.722) in MCF-pcDNA3 and -10.46 (95% CI: -10.66 
to -10.26) in MCF-OATP2B1. A significant difference was observed in the case of E1S 
treatment (P = 0.005). On the other hand, the logEC50 values for E2 were -11.56 (95% CI: 
-11.67 to -11.45) in MCF-pcDNA3 and -11.58 (95% CI: -11.74 to -11.43) in MCF-OATP2B1. 
There was no significant difference in the case of E2 treatment (P = 0.826). Estrogen-induced 
effects were mainly caused by the binding of E2 to ER followed by activation of genes 
possessing an ERE by the E2-ER complex [40]. Stimulation of ER was confirmed in this study 
by using a reporter gene expression under control of the ERE. As shown in Figure 7, the results 
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of the luciferase assay were consistent with those of the cell proliferation assay. The apparent 
logEC50 values for E1S were again significantly different (P = 0.039) between MCF-pcDNA3, 
-8.111 (95% CI: -8.303 to -7.919), and MCF-pcDNA3, -9.208 (95% Cl: -9.409 to -9.006). On 
the other hand, no significant difference in the logEC50 values for E2 (P = 0.808) was observed 
in MCF-pcDNA3, -12.67 (95% CI: -13.02 to -12.32), and MCF-OATP2B1, -12.69 (95% CI: 
-13.05 to -12.33). Most of E1S are thought to be converted into E2 in MCF-7 cells [41]. The E2 
concentrations in the medium were determined by ELISA after the addition of E1S. 
Overexpression of OATP2B1 caused a significant increase in E2 secretion at the four doses of 
E1S including physiological concentration (0.1 nM to 100 nM) (Figure 8).  
  
Uptake of E1S in ER-positive breast cancer cells 
To determine whether uptake of E1S contributes to the proliferation of ER-positive 
breast cancer cells, OATP functions were blocked by bromosulfophtalein (BSP), which is a 
universal inhibitor for OATPs. BSP blocked E1S-stimulated proliferation of MCF-7 cells 
(Figure 9). Next, the difference in the amount of E1S uptake between these cell lines was 
determined by using tritium-labeled E1S. The uptake of [
3
H]E1S (20 nM) in MCF-7 cells was 
significantly decreased with unlabeled E1S (0.1 mM) (Figure 10), suggesting that E1S was 
transported into the cells. The amount of uptake of [
3
H]E1S at stably state in MCF-OATP2B1 
-24- 
 
was significantly higher than that in MCF-pcDNA3 (Figure 10). Kinetic analysis of the uptake 
of E1S including physiological concentration (up to 20 μM from 10 nM) at 3 min after addition 
of [
3
H]E1S was performed on the basis of the results obtained for the time course of the uptake 
of E1S (Figure 11). The uptake of E1S by MCF-OATP2B1 was much greater than that by 
MCF-pcDNA3. 
 
Expression of SLCO2B1 mRNA in clinical samples and correlations between the expressions 
of SLCO2B1 mRNA and clinicopathological variables 
 Normal breast (n =16) and malignant tissue samples (n = 49) were collected and used 
in this study. The expression levels of mRNAs including those of SLCO2B1 and 
estrogen-related genes were determined by real-time RT-PCR. As shown in Figure 12, the 
expression level of SLCO2B1 mRNA in malignant tumors was significantly higher than that in 
normal tissues (P = 0.0001). The expression of SLCO2B1 mRNA in malignant tumors was 
studied in relation to clinicopathological parameters: age of the patient, tumor size, lymph node 
status, histological grade, ER status, PgR status, HER2 (human epidermal growth factor 
receptor 2) status and Ki-67 labeling index (LI) (Table 3). The expression level of SLCO2B1 
mRNA showed a significant increase when comparing histological grade 1 to 2 + 3 (P = 0.022). 
A significant positive correlation was also found in between the mRNA expression level of 
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SLCO2B1 and Ki-67 LI (P = 0.019). Correlations between expression levels of SLCO2B1 
mRNA and mRNAs of various transcripts including STS, ERα, CCNDI and Aromatase were 
analyzed by Pearson’s correlation (Table 4). A significant positive correlation was observed 
between the expression of SLCO2B1 and STS mRNAs (P < 0.001). There was no significant 
correlation between the expression levels of SLCO2B1 and ERα mRNAs, while the mRNA 
expression level of ERα mRNA was significantly correlated with that of CCNDI mRNA, which 
has been reported as one of estrogen-dependent transcripts.  
 
Down-regulation of ERα and induction of Ki-67 by the uptake of E1S in MCF-7 cells 
Ki-67 LI is widely used to divide ER-positive breast cancers into two subtypes, 
luminal A-like and luminal B-like cancers, and to determine whether chemotherapy agents are 
needed together with endocrine treatment [26]. In this study, we found a significant correlation 
between the expression level of SLCO2B1 mRNA and Ki-67 LI (Table 3). As shown in Figure 
13, the expression of SLCO2B1 mRNA in luminal B-like cancers tended to be higher than that 
in luminal A-like cancers, and the difference was a statistical trend toward significance (P = 
0.072). The expression levels of ER and ER-related genes, such as PgR, in luminal B-like 
cancers are generally lower than those in luminal A-like cancers, and loss of the expression of 
PgR is associated with a lower ER expression level [25, 30-32]. Our cell-based assay revealed 
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that the high expression level of OATP2B1 caused an increase in the amount of intracellular 
E1S, and the uptake of E1S may correlate with proliferation of ER-positive breast cancer cells. 
Thus, the relationship among uptake of E1S and expressions of ERα and Ki-67 was examined in 
MCF-7 cells by blocking OATP functions with BSP. According to the several reports [42-44], 
incubation for at least 24 h and 48 h must be necessary to confirm down-regulation of ER 
mRNA and protein, respectively. The expression of ERα mRNA was not changed by the 
addition of E1S (Figure 14), whereas the expression of ERα protein in MCF-7 cells was clearly 
decreased by the presence of E1S (Figure 15). Importantly, the reduction of ERα protein 
expression was blocked by BSP (Figure 15). On the other hand, both expressions of Ki-67 
mRNA and protein were induced by the presence of E1S, and the induction of Ki-67 protein 
expression was blocked by BSP (Figures 14 and 15). Taken together, the uptake E1S into 
ER-positive cancer cells caused down-regulation of ERα and induction of Ki-67. 
  
Expression of other SLCO mRNAs in breast cancer tissues 
The expression profiles of OATPs in breast cancer-derived cell lines are known to be 
different from those in breast cancer tissues [45-47]. As shown in Figure 16, the expression 
level of SLCO2B1 mRNA in a malignant tissue was approximately 4,000-times higher than that 
in MCF-7 cells. On the other hand, other OATPs are known to transport E1S along with 
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OATP2B1 [18, 19]. We selected seven OATPs in this study which have been reported to 
recognize E1S as a substrate, and the differences in expression profiles of these SLCO mRNAs 
among normal breast tissues, malignant tissues and MCF-7 cells were investigated. Expression 
of SLCO1A2, 2B1 and 3A1 mRNAs was detected in normal breast tissues, malignant tissues 
and MCF-7 cells, whereas the expression of SLCO1C1 mRNA was detected in only normal 
breast and malignant samples, and the other SLCO mRNAs were not detected in these tissues 
and MCF-7 cells (Figure 17). The differences in the expression levels of SLCO1A2, 3A1 and 
1C1 mRNAs determined by real-time PCR method are shown in Figure 18. The expression 
level of SLCO1A2 mRNA in malignant tumors was significantly higher than that in normal 
tissues (P = 0.0478), while no significant differences were observed in the expression levels of 
SLCO3A1 and SLCO1C1 mRNAs between normal tissues and malignant tumors.  
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Figure 2.  Western immunoblot analysis of OATP2B1 in 25 μg membrane proteins extracted 
from MCF-OATP2B1 and MCF-pcDNA3. Twenty-five μg membrane proteins collected from 
HEK-OATP2B1 and HEK-pcDNA3 were used as a positive control and mock, respectively. 
Na
+
/K
+
-ATPase was used as a loading control of membrane proteins from each cell line. 
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Figure 3.  Effect of enzymatic deglycosylation on the apparent molecular mass of human 
OATP2B1. The membrane proteins extracted from each cell line were deglycosylated by 
incubating with Protein Deglycosylation Mix containing PNGase F, O-Glycosidase, 
Neuraminidase, β1-4 Galactosidase and β-N-acetylglucosaminidase for 4 h. After the 
deglycosylated reaction, proteins were precipitated by acetone, and 30 μg proteins were 
analyzed by SDS-PAGE and Western immunoblot analysis. 
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Figure 4.  Immunocytochemistry for detection of human OATP2B1 overexpressed in MCF-7 
cells. The nuclei and OATP2B1 are shown as blue and brown, respectively. Bar represents 20 
μm. 
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Figure 5.  Basal cell proliferation of MCF-pcDNA3 and MCF-OATP2B1. These cells were 
pre-cultured in estrogens-free medium for 2 days. The day after pre-culturing, the medium was 
changed into estrogens-contained medium or estrogens-free medium and the cell number was 
counted after the desired period of days. All of the values represent the mean of triplicates ± SD. 
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Figure 6.  Results for proliferation of MCF-OATP2B1 and MCF-pcDNA3 after addition of 
(A) E2 or (B) E1S. These cells were pre-cultured in estrogens-free medium for 2 days. The day 
after pre-culturing, E2, E1S or DMSO was added and the cell number was counted 5 days later. 
All of the values represent the mean of triplicates ± SD. *P < 0.05, ** P < 0.01 and *** P < 
0.001 compared with MCF-pcDNA3 and MCF-OATP2B1. 
 
 
 
A 
B 
-33- 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Results of the luciferase assay to investigate stimulation of ER in MCF-OATP2B1 
and MCF-pcDNA3 after addition of (A) E2 or (B) E1S. These cells were pre-cultured in 
estrogens-free medium for 2 days. The day after pre-culturing, the cells were co-transfected 
with pGL3-ERE and renilla luciferase vector pGL4.74. At 6 h after transfection, E2, E1S or 
DMSO was added and luciferase activities were determined 36 h later. All of the values 
represent the mean of triplicates ± SD. * P < 0.05 and ** P < 0.01 compared with 
MCF-pcDNA3 and MCF-OATP2B1. 
 
A 
B 
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Figure 8.  E2 secretion by MCF-pcDNA3 and MCF-OATP2B1 after the addition of E1S. 
These cells were pre-cultured in estrogens-free medium for 2 days. The day after pre-culturing, 
E1S or DMSO was added and the E2 concentrations were measured 72 h later. All of the values 
represent the mean of quadruplicate ± SD. *** P < 0.001 compared with MCF-pcDNA3 and 
MCF-OATP2B1. 
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Figure 9.  Effect of inhibition of E1S uptake via OATPs on hormone-dependent growth of 
MCF cells after addition of E1S in the presence or absence of BSP. The cells were pre-cultured 
in estrogens-free medium for 2 days. The day after pre-culturing, E1S or DMSO was added with 
or without BSP, and the cell number was counted 5 days later. White boxes, control cells; black 
boxes, constant amount of E1S with varying concentrations of BSP; grey boxes, constant 
amount of BSP with varying concentrations of E1S. * P < 0.05 and ** P < 0.01 compared with 
the cell number after addition of 10 nM E1S. 
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Figure 10.  Basal uptake of E1S by MCF-7 cells and the difference in the uptake of E1S 
between MCF-pcDNA3 and MCF-OATP2B1 at steady state (at 37℃ for 30 min). [3H]E1S, 20 
nM [
3
H]E1S; +E1S, 20 nM [
3
H]E1S with 0.1 mM unlabeled E1S; pcDNA3, Uptake of 20 nM 
[
3
H]E1S in MCF-pcDNA3; OATP2B1, Uptake of 20 nM [
3
H]E1S in MCF-OATP2B1. All of the 
values represent the mean of triplicates ± SD. ***P < 0.001 compared with the difference in 
mean values between two groups. 
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Figure 11.  (A) Time course of [
3
H]E1S (20 nM) uptake by MCF-OATP2B1 and 
MCF-pcDNA3. These cells were incubated at 37℃ for 20 min in TB containing 20 nM 
[
3
H]E1S. (B) Dose-concentration plot of E1S uptake by the cells. Ratios of [
3
H]E1S uptake by 
the cells at varying concentrations up to 20 μM from 10 nM were determined at 37℃ for 3 min. 
The kinetic parameters were estimated by least-square nonlinear regression analysis using Prism 
5.01 software. All of the values represent the mean of triplicates ± SD. 
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Figure 12.  Difference in the expression of SLCO2B1 mRNA between normal breast tissues 
(NB) and breast cancer tissues (BC). The mRNA expression was assessed in NB and BC 
obtained from 16 female individuals by using real-time PCR. Data represent the ratio of the 
average in NB ± SE. 
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Table 3.  Correlations between expression of SLCO2B1 mRNA and clinicopathological 
variables in 49 breast cancer tissues 
 
 
 
 
 
 
 
 
 
 
P < 0.05 was considered significant, and significant values are shown in boldface. 
 
 
 
Clinical parameter n SLCO2B1 mRNA expression (mean ± SE) P  value
Age
<50 years 23 2.30 ± 0.47
≥50 years 26 3.60 ± 0.93
Tumour size
≤2 cm 18 3.16 ± 0.75
>2 cm 31 2.89 ± 0.75
Lymph node status
Positive 27 2.19 ± 0.41
Negative 22 3.97 ± 1.08
Histological grade
1 14 1.66 ± 0.26
2 + 3 35 3.52 ± 0.74
ER
Positive 40 3.71 ± 1.35
Negative 9 2.83 ± 0.60
PgR
Positive 37 5.10 ± 1.88
Negative 12 2.30 ± 0.34
HER2
Positive 7 2.67 ± 0.70
Negative 42 3.04 ± 0.62
Ki-67 labelling index
49 r = 0.335 0.019
0.169
0.693
0.220
0.795
0.132
0.022
0.563
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Table 4.  Correlations between expression of SLCO2B1 mRNA and levels of various 
transcripts in 49 breast cancer tissues 
 
 
 
 
 
Pearson's correlation coefficient (P value) 
P < 0.05 was considered significant, and significant values are shown in boldface. 
 
 
 
 
 
 
 
Aromatase - - - - 1
CCDNI - - - 1 -0.096 (0.511)
ERα - - 1 0.558 (< 0.001) -0.026 (0.858)
STS - 1 0.074 (0.615) 0.116 (0.428) 0.075 (0.610)
SLCO2B1 1 0.442 (0.001) -0.030 (0.840) 0.177 (0.223) 0.009 (0.954)
Gene name SLCO2B1 STS ERα CCDNI Aromatase
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Figure 13.  Difference in the expression of SLCO2B1 mRNA between two luminal subtypes 
of breast cancer, luminal A-like and luminal B-like cancers. Luminal B-like cancers were 
defined as ER-positive cases with HER2-negative and Ki-67 LI ≧ 15%. Data represent the 
ratio of the average in NB ± SE. 
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Figure 14.  Alteration of the expression levels of ERα and Ki-67 mRNAs by the addition of 
E1S in MCF-7 cells. These cells were pre-cultured in estrogens-free medium for 2 days. The 
day after pre-culturing, E1S (10 nM) or DMSO was added and mRNA was collected. The 
expression of mRNA was assessed by using real-time PCR. Data represent the ratio of the 
average in DMSO control at each time ± SD. 
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Figure 15.  (A) Alteration of the expression levels of ERα and Ki-67 proteins by the addition 
of E1S in MCF-7 cells and (B) band intensity of ERα and Ki-67 protein expressions obtained 
from Western blot analysis. These cells were pre-cultured in estrogens-free medium for 2 days. 
The day after pre-culturing, E1S (10 nM) or DMSO was added with or without BSP (100 μM). 
BSP was used to inhibit the uptake of E1S into the cells, and total protein was collected 72 h 
later. Data represent the ratio of the average in 0 h DMSO control ± SD. 
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Figure 16.  Difference in the expression of SLCO2B1 mRNA between the MCF-7 cell line and 
a breast tissue. The breast tissue was randomly chosen from breast tumors collected in this study. 
Data represent the ratio of the expression level in MCF-7 ± SD. 
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Figure 17.  Expression profile of OATP transporter mRNAs in the MCF-7 cell line, normal 
breast tissues (NB) and cancer tissue (BC). These normal breast and cancer tissues were 
randomly chosen from tissues obtained in this study. MCF, MCF-7 cells; PC, positive control 
for detection of each transporter mRNA expression. 
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Figure 18.  Difference in the expression levels of SLCO1A2, SLCO3A1 and SLCO1C1 
mRNAs between normal breast tissues (NB) and breast cancer tissues (BC). The mRNA 
expression was assessed in NB and BC obtained from 16 female individuals by using real-time 
PCR. Data represent the ratio of the average in NB ± SE. 
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Discussion 
 There has been no study in which various effects of overexpression of OATP in breast 
cancer-derived cell lines were examined. In the present study, MCF-7 cells stably 
overexpressing one of the OATPs, OATP2B1, were established for the first time and used as a 
model of OATP-overexpressed ER-positive breast cancer cells. The apparent molecular size of 
OATP2B1 expressed in MCF-7 cells was approximately 116 kDa. It has been reported that 
OATP2B1 expressed in Caco-2 cells (human epithelial colorectal adenocarcinoma cells) and 
MDCKII cells (Madin-Darby canine kidney cells) shows a robust band at approximately 84 kDa 
as was found in our HEK293 cells [48, 49]. Regarding this discrepancy, we found that 
deglycosylation of OATP2B1 shifted the band size to about 59 kDa in both MCF-7 and 
HEK293 cells in this study. Hänggi et al. reported that the apparent molecular size of OATP2B1 
stably expressed in CHO-K1 cells (Chinese hamster ovary cells) was approximately 75 kDa and 
that deglycosylation of OATP2B1 yielded a protein with a band size of approximately 55 - 60 
kDa [50]. These findings indicate that the apparent molecular size of OATP2B1 is dependent on 
the type of cells, and the reason for the discrepancy is posttranslational modifications including 
glycosylation.  
The uptake of E1S in both MCF-7 cells and T-47D cells, the latter of which is another 
ER-positive breast cancer-derived cell line, has been demonstrated to be mediated by a 
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carrier-mediated transport mechanism, and inhibition of E1S uptake is thought to be a good 
candidate as a novel target for ER-positive breast cancer [51, 52]. Consistent with these reports, 
we observed that the uptake of E1S into MCF-7 cells stimulated ER, and inhibition of E1S 
uptake by BSP resulted in the suppression of hormone-dependent proliferation of MCF-7 cells. 
The plasma concentration of E1S is approximately 1 to 10 nM [53-55], whereas the Km value 
for E1S by OATP2B1 is reported to be 5 to 21 μM [19]. We found that the cell proliferation, 
ER-mediated transcriptional activities and E2 secretion were stimulated by addition of 
physiological concentration of E1S to the culture medium in MCF-7 cells. Moreover, we 
showed that overexpression of OATP2B1 enhanced these stimulatory effects. These data 
suggest that the physiological concentration of E1S is sufficient to stimulate proliferation of 
breast cancer cells, and the difference in the expression levels of uptake transporters for E1S 
affects cell proliferation in ER-positive breast cancer by changing the amount of intracellular 
estrogens. 
Seven OATPs, OATP1A2, OATP1B1, OATP1B3, OATP1C1, OATP2B1, OATP3A1 
and OATP4A1, have been reported to recognize E1S as a substrate [18, 19]. Although some of 
them or their transcripts were detected in breast cancer-derived cell lines and breast tissues, the 
expression profiles of OATPs were different between cell lines and breast tissues in the present 
study. In addition to reports about differences in the expression profiles of OATPs among breast 
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cancer-derived cell lines [45-47], Maeda et al. obtained two subclones of MCF-7 cells with 
different E1S uptake activities and examined the contribution of OATP1B3 to E1S uptake by 
MCF-7 cells using the relative activity factor method [56]. From these, the expression of OATPs 
may be heterogeneous or depend on the condition of each cell line. Several OATPs whose 
expressions were detected in breast tissues, including OATP1A2, OATP1B3, OATP3A1 and 
OATP5A1, have been suggested to be related to proliferation of breast cancer cells, while very 
little is known about the function and characteristics of OATP5A1 [47, 57-60]. It is possible that 
some OATPs have the responsibility for uptake of E1S into breast cancer cells. On the other 
hand, the Km value for E1S uptake by OATP2B1 is lower than that by other OATPs, although it 
depends on reports [16, 19]. Sai et al. have examined the contribution of OATP2B1 to the 
uptake of E1S in Caco-2 cells in comparison with those of its homologs OATP3A1 and 
OATP4A1 [35]. They have suggested that contribution of OATP2B1 for the uptake of E1S may 
be much greater than other OATPs. Overexpression of OATP2B1 dramatically increased in the 
uptake of E1S into MCF-7 cells in the present study. Based on these, it is likely that OATP2B1 
have a significant role for uptake of E1S in breast cancer cells. 
Breast cancer-derived cell lines, such as MCF-7 cells, seem to have very low levels of 
OATP2B1 as compared to breast tissues [45]. On the other hand, abundant expression of 
SLCO2B1 mRNA and OATP2B1 protein in breast tissues were detected in our study and other 
-50- 
 
two previous reports [24, 59], although we could not detect clear expression of OATP2B1 
protein in breast tissues due to nonspecific binding of antibodies to the target protein (data not 
shown). According to the finding of the abundant expression of SLCO2B1 mRNA in our study 
and the previous reports, breast cancer cells in the patients appear to express a significant 
amount of OATP2B1 protein. A high expression level of STS mRNA has been reported to be 
significantly associated with poor prognosis, and the expression of STS mRNA is thought to be 
as a significant prognostic factor in ER-positive breast cancer [61]. Interestingly, in their work, a 
significant correlation between the expression of STS mRNA and poor prognosis was observed 
in ER-positive samples but not in ER-negative samples. STS immunoreactivity has also been 
reported to be significantly correlated with poor prognosis of breast cancer [62]. Therefore, 
inhibition of STS has been becoming an attractive therapeutic strategy for ER-positive breast 
cancer [10, 11, 63]. A significant correlation between mRNA expression levels of SLCO2B1 
and STS was found in our study (Table 4). Moreover, an increase in the amount of E2 by the 
addition of E1S in MCF-7 cells was observed (Figure 8). These data may indicate that both STS 
and OATP2B1 help each other to produce active estrogens from E1S in ER-positive breast 
cancer. A breast cancer with high expression levels of both SLCO2B1 and STS mRNAs might 
be classified into a more aggressive subtype, and inhibition both STS and OATP2B1 may result 
in suppression of cell proliferation in ER-positive breast cancer.  
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The expression level of SLCO2B1 mRNA in breast cancers was significantly 
correlated with histological grade and Ki-67 LI in the present study (Table 3). A significant 
relationship between the expression of SLCO2B1 mRNA and histological grade in breast 
tumors was also reported by another group [64]. Expression of Ki-67 is strongly correlated with 
poor prognosis and clinicopathological variables of breast cancers, including tumor size, nodal 
status and histological grade in breast cancer [65, 66]. The 13
th
 St Gallen Conference 
recommended using a combination of ER, PgR and Ki-67 to segregate luminal A-like and 
B-like cancers in a clinical setting [67]. Although standardized cut-offs for Ki-67 LI have been 
augmented and have not been established yet, a threshold of ≧ 15 - 20% probably indicates a 
high level of Ki-67 expression. Since the most commonly used threshold is ≧ 15%, we have 
routinely assigned tumor cells with ≧ 15% positive staining of Ki-67 LI as luminal B-like 
cancer cells. When we used the cut-off of 20%, the difference between the expression levels of 
SLCO2B1 mRNA in luminal A-like and B-like cancers was significant (P = 0.023). We also 
showed that the uptake of E1S caused down-regulation of ERα and induction of Ki-67 in 
MCF-7 cells (Figures 14 and 15). Thus, the expression levels of SLCO2B1 mRNA may be 
correlated with proliferation of breast cancer cells and luminal-B like cancers from the present 
study. 
The reason why the expression level of SLCO2B1 mRNA in liminal B-like cancers 
-52- 
 
was higher than that in luminal A-like cancers is unknown. The result seems to be inconsistent 
with the characteristics of luminal B-like cancers, because some of luminal B-like cancers show 
estrogen-independent growth and resistant to endocrine therapy. Luminal B-like cancer cells are 
believed to evolve from luminal A-like cancers, and loss of ER function and genomic alterations 
well occur during the progression of breast cancer to a hormone-resistant state [68, 69]. 
Considering these reports and the present study, OATPs might have an important role to 
maintain estrogen-dependent signaling with down-regulation of ER and induction of Ki-67 in 
the path from luminal A-like to luminal B-like cancers via increase in the amount of 
intracellular E2. Once luminal A-like cancers obtain an alternative pathway in addition to 
ER-dependent signaling pathway, the cancer cells might gradually become to show 
ER-independent growth. Luminal B-like cancers seem to be a complex of various ER-positive 
cases, and this subtype might be an intermediate type between luminal A-like cancers and other 
subtypes of breast cancer. In fact, luminal B-like caners share some gene expression patterns 
with both luminal A-like and triple negative cancers [69]. Taken together, the uptake of E1S by 
OATP2B1 followed by continuous stimulation of ER by E2 may cause down-regulation of ERα 
and induction of Ki-67. These might be associated with high expression levels of proliferation 
markers, such as Ki-67, and low expression levels of estrogen-related genes, such as PgR, in 
luminal B-like cancer.  
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The mechanisms of the high expression level of SLCO2B1 mRNA in breast cancer are 
unknown. It has been reported that the expression level of pregnane X receptor (PXR) was 
correlated with progression or differentiation of breast cancer [57, 70]. PXR is known to 
positively regulate transcription of many genes including several OATPs, and it is thought to be 
a key regulator of xenobiotic metabolism. The above two studies also showed by microarray 
analysis that the expression level of PXR is related to that of OATP1A2 in breast cancer and 
suggested that both OATP1A2 and PXR contribute to the pathogenesis of breast cancer. The 
authors of those reports showed that OTAP2B1 and OATP1A2 were clustered in different 
groups, indicating that other factors may be associated with regulation of the expression level of 
OATP2B1 in breast cancer. Constitutive androstane receptor (CAR), aryl hydrocarbon receptor 
(AhR), peroxisome proliferator-activated receptor α (PPARα), nuclear factor erythroid 2-related 
factor 2 (Nrf2) and protein kinase C (PKC), all of which might be able to regulate the 
expression level of OATP2B1, are enumerated as candidates of the factor [71-73]. The 
relationship among alteration of the expression level of OATP2B1 and these transcriptional 
factors in MCF-7 cells should be investigated in another study. 
The hypothetical scheme of the present study is summarized in Figure 19. We 
emphasize that the scheme can be applied only for ER-positive cases, luminal A-like and B-like 
cancers, excluding ER-positive cases that are positive for HER2 (luminal-HER2). The St Gallen 
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Consensus also distinguishes luminal-HER2 subtypes from luminal A-like and B-like cancers 
[68]. In fact, we found that the proliferation of BT474 cells, which is considered to be one of the 
luminal-HER2 cell lines [74], was not clearly stimulated by the addition of E1S (data not 
shown). In addition, the correlation between the expression of SLCO2B1 mRNA and Ki-67 LI 
was more significant when analyzing only ER-positive cases without luminal-HER2 ones (P = 
0.004). Considering these data, the uptake of E1S does not seem to be essential for other 
subtypes, such as HER2-positive and triple negative cases. However, the number of 
HER2-positive and triple negative cases in the present study was small. A larger number of 
clinical samples and assessment of the expression of OATP2B1 protein are needed to analyze 
the relationship between the expression level of OATP2B1 and subtypes of breast cancer in a 
future study. Moreover, it would be of great interest to investigate the effects of expression level 
of OATP2B1 on chemotherapy or endocrine therapy. 
The present study focused on uptake of E1S in ER-positive breast cancer cells, but 
efflux of E1S in the cancer cells was not investigated. Breast cancer resistance protein (BCRP) 
exhibits efflux of E1S in Caco-2 cells [75]. The Km value for E1S by BCRP is reported to be 
approximately 7 to 11 μM [76, 77]. The expression of BCRP protein has been detected in breast 
cancer tissues, and it is possible that BCRP has some responsibility for efflux of E1S in breast 
cancer cells [78, 79]. On the other hand, Imai et al. found a marked decrease in the expression 
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of BCRP protein after addition of E2 to ER-positive breast cancer cells overexpressing BCRP, 
MCF-7/BCRP cells and T-47D/BCRP cells, but not ER-negative breast cancer cells 
overexpressing BCRP, MDA-MB-231/BCRP cells [80]. The decrease in the expression of 
BCRP was inhibited by antiestrogen agent tamoxifen and abolished by ER small interfering 
RNA, suggesting that the decrease of BCRP needs interaction of ER and E2. We demonstrated 
that uptake of E1S resulted in enhancement of E2 secretion in MCF-7 cells. It is considered that 
ER-mediated actions occur after conversion of E1S into E2 in ER-positive cancer cells. Even 
though ER-positive breast cancer has the pathway for elimination of E1S by BCRP, the rate for 
influx of E1S might be grater than that for efflux of E1S in ER-positive breast cancer cells due 
to uptake of E1S followed by interaction of ER and E2. ER-positive breast cancer cells therefore 
seem to accumulate intracellular estrogens by the decrease of BCRP. However, the relationship 
between the expression level of BCRP and cell proliferation of ER-positive breast cancer cells 
needs to be investigated in another study. 
 
 
 
 
 
-56- 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  Summary of hypothetical scheme for uptake of estrogen precursors into breast 
cancer cells and the relationships between uptake of E1S and luminal subtypes.  
 
 
 
 
 
 
-57- 
 
Conclusion 
The present study has demonstrated that OATP2B1 plays a key role in supplying 
ER-positive breast cancer cells with E1S and supporting cell proliferation in ER-positive breast 
cancer. High expression level of OATP2B1 might be associated with luminal B-like subtype due 
to down-regulation of ERα and induction of Ki-67 by uptake of E1S. The findings in this study 
lead us to conclude that OATP2B1 is involved in proliferation of ER-positive breast cancer cells 
by increasing the intracellular amount of estrogens in breast cancer cells. Moreover, OATP2B1 
might be useful as a novel target or biomarker for ER-positive breast cancer, especially luminal 
B-like cancer.  
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